Pulmonx CORP 8-K filings

Pulmonx Corporation announced its second quarter 2026 financial results, reporting a 5% decrease in worldwide revenue to $22.8 million, but a significant reduction in net loss and adjusted EBITDA loss due to cost realignment.

Pulmonx Corporation's 2026 Annual Meeting saw strong stockholder participation and approval of director nominees, auditor ratification, and executive compensation.

Pulmonx Corporation announced its fourth quarter and full year 2025 financial results, showing full-year revenue growth and reduced losses despite a Q4 revenue decline.

Pulmonx Corporation announced its third quarter 2025 financial results, reporting a 5% increase in worldwide revenue and reaffirming its commitment to profitable growth.

Pulmonx Corporation announced a significant leadership transition, reappointing Glendon E. French as President and CEO and Derrick Sung as COO and CFO, alongside preliminary Q3 2025 revenue of $21.5 million.

Pulmonx Corporation announced its second quarter 2025 financial results, reporting strong international revenue growth but revising its full-year revenue guidance lower due to slower U.S. market conversion.

Pulmonx Corporation announced the results of its 2025 Annual Meeting of Stockholders, where all director nominees were elected, the independent auditor was ratified, and executive compensation received a narrow advisory approval.

Pulmonx Corporation announced a 20% increase in worldwide revenue for Q1 2025, driven by growth in both U.S. and international markets and reaffirms full year 2025 revenue guidance.

Pulmonx Corporation announced record fourth quarter and full year 2024 financial results, driven by increased revenue and strategic initiatives.

Pulmonx Corporation announced a 15% year-over-year increase in worldwide revenue for the third quarter of 2024, reaching $20.4 million, driven by strong adoption of its Zephyr Valve treatment.

Pulmonx reported record worldwide revenue of $20.8 million for the second quarter of 2024, a 21% increase year-over-year, fueled by strong U.S. sales.

Pulmonx Corporation has amended its office lease and sublease agreements to expand its premises and extend its lease terms in Redwood City, California.

Pulmonx Corporation held its 2024 Annual Meeting of Stockholders, electing two Class I directors, ratifying its independent auditor, and approving executive compensation on an advisory basis.

Pulmonx Corporation announced a 30% year-over-year increase in worldwide revenue for the first quarter of 2024, driven by strong adoption of its Zephyr Valve treatment.

Pulmonx Corporation has appointed Mehul Joshi as its new Chief Financial Officer, effective April 3, 2024, succeeding interim CFO John McKune.

Pulmonx Corporation announced a 28% increase in worldwide revenue for 2023, reaching $68.7 million, with significant growth in the U.S. market.

Pulmonx Corporation announced the retirement of CEO Glen French and the appointment of Steve Williamson as the new President and Chief Executive Officer, effective March 15, 2024.